Abstract:In this Journal, Au and colleagues previously compared the potency of CoronaVac in the seroprotection against SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants,1 we went on to provide an immunoprotection profile of CoronaVac against Omicron variants. As the latest variant of concern (VOC), the immune escape of Omicron poses a severe threat to vaccination effectiveness and immune protection. Earlier studies indicated a substantial decrease in the neutralizing antibody (Nab) response strength and antibody titers against Omicron elicited by mRNA-based vaccines.

Antibody Efficacy of Inactivated Vaccine Boosters (coronavac) Against Omicron Variant from a 15-Month Follow-Up Study